Literature DB >> 29438698

Programming of Schwann Cells by Lats1/2-TAZ/YAP Signaling Drives Malignant Peripheral Nerve Sheath Tumorigenesis.

Lai Man Natalie Wu1, Yaqi Deng1, Jincheng Wang1, Chuntao Zhao1, Jiajia Wang1, Rohit Rao1, Lingli Xu2, Wenhao Zhou2, Kwangmin Choi1, Tilat A Rizvi1, Marc Remke3, Joshua B Rubin4, Randy L Johnson5, Thomas J Carroll6, Anat O Stemmer-Rachamimov7, Jianqiang Wu1, Yi Zheng1, Mei Xin1, Nancy Ratner1, Q Richard Lu8.   

Abstract

Malignant peripheral nerve sheath tumors (MPNSTs) are highly aggressive Schwann cell (SC)-lineage-derived sarcomas. Molecular events driving SC-to-MPNST transformation are incompletely understood. Here, we show that human MPNSTs exhibit elevated HIPPO-TAZ/YAP expression, and that TAZ/YAP hyperactivity in SCs caused by Lats1/2 loss potently induces high-grade nerve-associated tumors with full penetrance. Lats1/2 deficiency reprograms SCs to a cancerous, progenitor-like phenotype and promotes hyperproliferation. Conversely, disruption of TAZ/YAP activity alleviates tumor burden in Lats1/2-deficient mice and inhibits human MPNST cell proliferation. Moreover, genome-wide profiling reveals that TAZ/YAP-TEAD1 directly activates oncogenic programs, including platelet-derived growth factor receptor (PDGFR) signaling. Co-targeting TAZ/YAP and PDGFR pathways inhibits tumor growth. Thus, our findings establish a previously unrecognized convergence between Lats1/2-TAZ/YAP signaling and MPNST pathogenesis, revealing potential therapeutic targets in these untreatable tumors.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Lats1/2; MPNST; PDGF signaling; Schwann cells; TAZ; YAP; hippo signaling; murine models; peripheral nerve sheath tumor; tumor suppressor

Mesh:

Substances:

Year:  2018        PMID: 29438698      PMCID: PMC5813693          DOI: 10.1016/j.ccell.2018.01.005

Source DB:  PubMed          Journal:  Cancer Cell        ISSN: 1535-6108            Impact factor:   31.743


  47 in total

1.  Genomic and molecular characterization of malignant peripheral nerve sheath tumor identifies the IGF1R pathway as a primary target for treatment.

Authors:  Jilong Yang; Antti Ylipää; Yan Sun; Hong Zheng; Kexin Chen; Matti Nykter; Jonathan Trent; Nancy Ratner; Dina C Lev; Wei Zhang
Journal:  Clin Cancer Res       Date:  2011-10-31       Impact factor: 12.531

2.  Neural crest cells retain multipotential characteristics in the developing valves and label the cardiac conduction system.

Authors:  Tomoki Nakamura; Melissa C Colbert; Jeffrey Robbins
Journal:  Circ Res       Date:  2006-05-18       Impact factor: 17.367

3.  TAZ promotes cell proliferation and epithelial-mesenchymal transition and is inhibited by the hippo pathway.

Authors:  Qun-Ying Lei; Heng Zhang; Bin Zhao; Zheng-Yu Zha; Feng Bai; Xin-Hai Pei; Shimin Zhao; Yue Xiong; Kun-Liang Guan
Journal:  Mol Cell Biol       Date:  2008-01-28       Impact factor: 4.272

Review 4.  The Hippo pathway effectors TAZ and YAP in development, homeostasis and disease.

Authors:  Xaralabos Varelas
Journal:  Development       Date:  2014-04       Impact factor: 6.868

5.  Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles.

Authors:  Aravind Subramanian; Pablo Tamayo; Vamsi K Mootha; Sayan Mukherjee; Benjamin L Ebert; Michael A Gillette; Amanda Paulovich; Scott L Pomeroy; Todd R Golub; Eric S Lander; Jill P Mesirov
Journal:  Proc Natl Acad Sci U S A       Date:  2005-09-30       Impact factor: 11.205

6.  Phase II multicenter trial of imatinib in 10 histologic subtypes of sarcoma using a bayesian hierarchical statistical model.

Authors:  Rashmi Chugh; J Kyle Wathen; Robert G Maki; Robert S Benjamin; Shreyaskumar R Patel; Paul A Meyers; Paul A Myers; Dennis A Priebat; Denise K Reinke; Dafydd G Thomas; Mary L Keohan; Brian L Samuels; Laurence H Baker
Journal:  J Clin Oncol       Date:  2009-05-18       Impact factor: 44.544

7.  Alterations in the NF2/LATS1/LATS2/YAP Pathway in Schwannomas.

Authors:  Ji-Eun Oh; Takashi Ohta; Kaishi Satomi; Matthieu Foll; Geoffroy Durand; James McKay; Florence Le Calvez-Kelm; Michel Mittelbronn; Benjamin Brokinkel; Werner Paulus; Hiroko Ohgaki
Journal:  J Neuropathol Exp Neurol       Date:  2015-10       Impact factor: 3.685

8.  Comparative pathology of nerve sheath tumors in mouse models and humans.

Authors:  Anat O Stemmer-Rachamimov; David N Louis; Gunnlaugur P Nielsen; Cristina R Antonescu; Alexander D Borowsky; Roderick T Bronson; Dennis K Burns; Pascale Cervera; Margaret E McLaughlin; Guido Reifenberger; Michael C Schmale; Mia MacCollin; Richard C Chao; Karen Cichowski; Michel Kalamarides; Shanta M Messerli; Andrea I McClatchey; Michiko Niwa-Kawakita; Nancy Ratner; Karlyne M Reilly; Yuan Zhu; Marco Giovannini
Journal:  Cancer Res       Date:  2004-05-15       Impact factor: 12.701

9.  Inhibition of angiogenic and non-angiogenic targets by sorafenib in renal cell carcinoma (RCC) in a RCC xenograft model.

Authors:  J S P Yuen; M Y Sim; H G Siml; T W Chong; W K O Lau; C W S Cheng; H Huynh
Journal:  Br J Cancer       Date:  2011-03-15       Impact factor: 7.640

10.  Zeb2 recruits HDAC-NuRD to inhibit Notch and controls Schwann cell differentiation and remyelination.

Authors:  Lai Man Natalie Wu; Jincheng Wang; Andrea Conidi; Chuntao Zhao; Haibo Wang; Zachary Ford; Liguo Zhang; Christiane Zweier; Brian G Ayee; Patrice Maurel; An Zwijsen; Jonah R Chan; Michael P Jankowski; Danny Huylebroeck; Q Richard Lu
Journal:  Nat Neurosci       Date:  2016-06-13       Impact factor: 24.884

View more
  33 in total

1.  Epigenomic Reordering Induced by Polycomb Loss Drives Oncogenesis but Leads to Therapeutic Vulnerabilities in Malignant Peripheral Nerve Sheath Tumors.

Authors:  John B Wojcik; Dylan M Marchione; Simone Sidoli; Anissa Djedid; Amanda Lisby; Jacek Majewski; Benjamin A Garcia
Journal:  Cancer Res       Date:  2019-03-21       Impact factor: 12.701

2.  Single-Cell Transcriptomics in Medulloblastoma Reveals Tumor-Initiating Progenitors and Oncogenic Cascades during Tumorigenesis and Relapse.

Authors:  Liguo Zhang; Xuelian He; Xuezhao Liu; Feng Zhang; L Frank Huang; Andrew S Potter; Lingli Xu; Wenhao Zhou; Tao Zheng; Zaili Luo; Kalen P Berry; Allison Pribnow; Stephanie M Smith; Christine Fuller; Blaise V Jones; Maryam Fouladi; Rachid Drissi; Zeng-Jie Yang; W Clay Gustafson; Marc Remke; Scott L Pomeroy; Emily J Girard; James M Olson; A Sorana Morrissy; Maria C Vladoiu; Jiao Zhang; Weidong Tian; Mei Xin; Michael D Taylor; S Steven Potter; Martine F Roussel; William A Weiss; Q Richard Lu
Journal:  Cancer Cell       Date:  2019-08-29       Impact factor: 31.743

Review 3.  Malignant Peripheral Nerve Sheath Tumors: From Epigenome to Bedside.

Authors:  Justin Korfhage; David B Lombard
Journal:  Mol Cancer Res       Date:  2019-04-25       Impact factor: 5.852

4.  YAP-Mediated Recruitment of YY1 and EZH2 Represses Transcription of Key Cell-Cycle Regulators.

Authors:  Sany Hoxha; Alyssa Shepard; Scott Troutman; Huitian Diao; Joanne R Doherty; Michalina Janiszewska; Robert M Witwicki; Matthew E Pipkin; William W Ja; Michael S Kareta; Joseph L Kissil
Journal:  Cancer Res       Date:  2020-05-14       Impact factor: 12.701

5.  LATS2 Inhibits Malignant Behaviors of Glioma Cells via Inactivating YAP.

Authors:  Yi Shi; Decheng Geng; Yu Zhang; Min Zhao; Yan Wang; Yang Jiang; Rutong Yu; Xiuping Zhou
Journal:  J Mol Neurosci       Date:  2019-02-15       Impact factor: 3.444

Review 6.  Emerging therapeutic targets for neurofibromatosis type 1.

Authors:  James A Walker; Meena Upadhyaya
Journal:  Expert Opin Ther Targets       Date:  2018-05-07       Impact factor: 6.902

7.  A novel HDAC11 inhibitor potentiates the tumoricidal effects of cordycepin against malignant peripheral nerve sheath tumor through the Hippo signaling pathway.

Authors:  Po-Yuan Huang; I-An Shih; Ying-Chih Liao; Huey-Ling You; Ming-Jen Lee
Journal:  Am J Cancer Res       Date:  2022-02-15       Impact factor: 6.166

8.  Oncogenic RABL6A promotes NF1-associated MPNST progression in vivo.

Authors:  Jordan L Kohlmeyer; Courtney A Kaemmer; Joshua J Lingo; Ellen Voigt; Mariah R Leidinger; Gavin R McGivney; Amanda Scherer; Stacia L Koppenhafer; David J Gordon; Patrick Breheny; David K Meyerholz; Munir R Tanas; Rebecca D Dodd; Dawn E Quelle
Journal:  Neurooncol Adv       Date:  2022-04-09

Review 9.  Genetic Events and Signaling Mechanisms Underlying Schwann Cell Fate in Development and Cancer.

Authors:  Harish N Vasudevan; Calixto-Hope G Lucas; Javier E Villanueva-Meyer; Philip V Theodosopoulos; David R Raleigh
Journal:  Neurosurgery       Date:  2021-01-13       Impact factor: 4.654

10.  OLIG2 maintenance is not essential for diffuse intrinsic pontine glioma cell line growth but regulates tumor phenotypes.

Authors:  Yunfei Liao; Zaili Luo; Yaqi Deng; Feng Zhang; Rohit Rao; Jiajia Wang; Lingli Xu; Shiva Senthil Kumar; Satarupa Sengupta; Mariko DeWire-Schottmiller; Kalen Berry; Matthew Garrett; Maryam Fouladi; Rachid Drissi; Qing Richard Lu
Journal:  Neuro Oncol       Date:  2021-07-01       Impact factor: 12.300

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.